Replimune/$REPL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Replimune
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Ticker
$REPL
Sector
Primary listing
Employees
479
Headquarters
Website
Replimune Metrics
BasicAdvanced
$405m
-
-$3.44
0.75
-
Price and volume
Market cap
$405m
Beta
0.75
52-week high
$13.24
52-week low
$1.50
Average daily volume
10m
Financial strength
Current ratio
5.597
Quick ratio
5.432
Long term debt to equity
34.327
Total debt to equity
36.262
Interest coverage (TTM)
-40.70%
Profitability
EBITDA (TTM)
-318.881
Effective tax rate (TTM)
0.13%
Management effectiveness
Return on assets (TTM)
-43.24%
Return on equity (TTM)
-90.88%
Valuation
Price to book
1.86
Price to tangible book (TTM)
1.86
Price to free cash flow (TTM)
-1.588
Free cash flow yield (TTM)
-62.96%
Free cash flow per share (TTM)
-3.091
Growth
Earnings per share change (TTM)
12.16%
3-year earnings per share growth (CAGR)
6.33%
What the Analysts think about Replimune
Analyst ratings (Buy, Hold, Sell) for Replimune stock.
Replimune Financial Performance
Revenues and expenses
Replimune Earnings Performance
Company profitability
Replimune News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs